期刊
CELLULAR IMMUNOLOGY
卷 208, 期 1, 页码 9-17出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1006/cimm.2001.1769
关键词
B lymphocytes; CD40; cellular activation; gene expression; cytokine; immune response modifier; signal transduction
资金
- NCI NIH HHS [CA66570] Funding Source: Medline
- NIAID NIH HHS [AI289847] Funding Source: Medline
- NIDDK NIH HHS [DK25295] Funding Source: Medline
Members of the imidazoquinoline molecule family, including imiquimod and resiquimod (R-848), have potent antiviral and antitumor activities. Imiquimod cream (5%) (Aldara) is currently indicated for treatment of external genital and perianal warts. Previous characterization of these compounds has focused upon their ability to activate monocytes and dendritic cells, but recent studies have shown that resiquimod also stimulates B lymphocytes to proliferate and express an activated phenotype. This suggests that resiquimod could potentially serve as an effective vaccine adjuvant in stimulating a humoral immune response. This study shows that resiquimod mimics effects of the T-dependent CD40 signal in both mouse and human B cell lines. Resiquimod, like CD40, stimulates antibody secretion, cytokine production, protection from apoptosis, and CD80 upregulation. In addition, it shows synergy with signals delivered by the B cell antigen receptor and heightens CD40-mediated B cell activation, demonstrating that resiquimod can enhance antigen-specific responses in B lymphocytes. (C) 2001 Academic Press.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据